Martyn Irvine has said he is very much looking forward to getting stuck into his new role with Cycling Ireland following ...

The milestone achievement places NMC Royal Hospital DIP among a select group of only 229 hospitals worldwide to earn this ...

Revolution Medicines (RVMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami ...

Discover Cardiff Oncology's promising results with Onvansertib for RAS-mutated colorectal cancer, potentially leading to ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung ... the discovery and ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Ras Al Khaimah, United Arab Emirates: Ras Al Khaimah Tourism Development Authority (RAKTDA) has been named a winner for the ...

Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the ...

On Thursday, Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced safety, tolerability, pharmacokinetic (PK), and preliminary ...

Classically, rational drug combinations are designed to target two nodes in the same oncogenic signalling pathway. BRAF and downstream mitogen-activated extracellular signal-regulated kinase (MEK) ...